Healthcare

Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development

Recursion Pharmaceuticals partners with MIT for Boltz-2, an AI model predicting binding affinity at unprecedented speed and accuracy.

Taysha Gene Therapies Stock (TSHA): Innovative Gene Therapy Focus

Taysha Gene Therapies (NASDAQ: TSHA) is gaining investor attention with TSHA-102, its lead Rett syndrome gene therapy. Learn why this biotech stock is a rising contender in the CNS space.

Cidara Therapeutics Stock (CDTX): A Notable Contender in Antivirals

Cidara Therapeutics aims to innovate antivirals with CD388, targeting flu prevention. Positive trial results may boost stock.

Hims & Hers Health (HIMS): Growth Amid Regulatory Challenges

Hims & Hers saw strong revenue growth but faces margin pressure and new FDA rules on weight-loss drugs. Can it adapt? Here’s what retail investors need to know.

Illumina Inc. (ILMN): Navigating Trade Restrictions Amid Rising Competition

China's ban on Illumina’s gene-sequencing machines escalates trade tensions, opening market share to domestic rivals. Investors should watch for biotech volatility.

Walgreens Boots Alliance Inc. (WBA): Upcoming Acquisition by Sycamore Partners

Sycamore Partners nears a $10B Walgreens buyout, potentially breaking up the retail giant. What it means for investors, market dynamics, and strategic shifts.

FAQs on Medicus Pharma's Interim Data Update - 6 March 2025

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a novel skin cancer treatment. Here are FAQs explaining this breakthrough.

Interim Data Update from Medicus Pharma’s Phase 2 Clinical Trial

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a revolutionary skin cancer treatment. Key details on this major breakthrough.

2Seventy Bio (TSVT): Surge Following Acquisition Announcement

2Seventy Bio jumps 77% as Bristol Myers Squibb announces a $5-per-share buyout. Learn how this deal reshapes biotech investing and what it means for you.

Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts

Gilead Sciences shares fall amid reports of potential federal funding cuts for HIV initiatives, raising concerns for investors.

Haleon (HLN): Pfizer Sells Stake in Consumer Healthcare Firm

Pfizer has finalized its exit from Haleon by selling its remaining stake for £2.5 billion, marking a significant milestone for the firm.

23andMe (NASDAQ: ME): Bankruptcy Filing and Strategic Sale Process

23andMe has filed for Chapter 11 to maximize business value while facing a steep decline, leadership change, and investment risks surrounding genetics.

Eli Lilly and Co (NYSE:LLY): Promising Breakthrough in Weight-Loss Treatments

Eli Lilly's orforglipron shows promise as a weight-loss pill, boosting shares by 12% and marking a major milestone in diabetes treatment.

Roche (RHHBY): Significant U.S. Investment to Enhance Manufacturing and Innovation

Roche plans to invest $50 billion in the U.S., creating over 12,000 jobs and expanding its manufacturing and R&D capabilities.